⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620821 | 0.70 | — | — | |
| SCHEMBL10935127 | 0.67 | — | — | |
| SCHEMBL7215917 | 0.65 | — | — | |
| SCHEMBL3999555 | 0.64 | — | — | |
| SCHEMBL10609471 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL18422639 | 0.64 | — | — | |
| SCHEMBL11755943 | 0.58 | — | — | |
| SCHEMBL872341 | 0.58 | — | — | |
| SCHEMBL2398119 | 0.57 | — | — | |
| SCHEMBL7273937 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | claimed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | claimed |
| WO-2023065014-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2023-04-27 | — | — | WO | claimed |
| CN-111378595-B | Burkholderia agricultural biocontrol strain Ba1 and application thereof | 中国林业科学研究院亚热带林业研究所 | 2021-04-27 | — | — | CN | claimed |
| US-20260137666-A1 | N-methyl-D-aspartic Acid Receptor Modulators | EMORY UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544363-B2 | N-methyl-D-aspartic acid receptor modulators | EMORY UNIVERISTY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240424113-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4419531-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2024-08-28 | — | — | EP | disclosed |
| US-20240199617-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| WO-2024086569-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086570-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2013143663-A1 | BICYCLIC PYRAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013040321-A1 | KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF | UNIVERSITY OF KANSAS (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| EP-1261611-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |